Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06961617Phase 1Recruiting

Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

Role: lead

NCT05195294Phase 2Not Yet Recruiting

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Role: lead

NCT04745403Phase 1Recruiting

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

Role: lead

NCT03634683Phase 1Withdrawn

A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation

Role: lead

NCT02686372Phase 1Completed

A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

Role: lead

NCT04677088Phase 1Unknown

TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation

Role: collaborator

NCT03899415Phase 1Unknown

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

Role: collaborator

NCT02719782Phase 1Unknown

A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

Role: lead

All 8 trials loaded